Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22503353 | 0.91 | NPR3 (0.35) | NPR3FOLH1 | |
| SCHEMBL21625918 | 0.90 | NPR3 (0.33) | NPR3FOLH1 | |
| SCHEMBL22503374 | 0.88 | — | — | |
| SCHEMBL18879824 | 0.88 | — | — | |
| SCHEMBL19335150 | 0.88 | — | — | |
| SCHEMBL19861842 | 0.82 | FOLH1 (0.35) | NPR3FOLH1 | |
| SCHEMBL790384 | 0.80 | NPR3 (0.41) | NPR3FOLH1 | |
| SCHEMBL789730 | 0.80 | NPR3 (0.41) | NPR3FOLH1 | |
| SCHEMBL790021 | 0.80 | NPR3 (0.41) | NPR3FOLH1 | |
| SCHEMBL23520088 | 0.80 | FOLH1 (0.35) | NPR3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10793591-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10420788-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-9598457-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | NPR3 1695/4885FOLH1 1161/4885 |
| US-10420788-B2 | — | PNP, ADAR, NT5C2 | NPR3 2278/4885FOLH1 2581/4885 |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | NPR3 1489/4885FOLH1 1566/4885 |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | NPR3 1695/4885FOLH1 1161/4885 |
| US-10793591-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C2 | NPR3 1695/4885FOLH1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.